

<b>Tender #</b>	<b>Tenderer Name and Address</b>	<b>Exclusion - Declaration on honor</b>
1	AstraZeneca	Yes/No

<b>Evidence provided (extract of judicial record/evidence social contributions and taxes are not due)</b>	<b>Clarifications needed (if any)</b>	
		<b>OK - Y/N</b>
		Y/N

No	Criterion	Documents to be submitted regarding criterion	Evidence provided	Comments
F1	The tenderer must prove to be financially viable to fulfil its obligations under the APA during the project development phase of the next twelve months. Financial viability of the tenderer will be checked by calculating a survival ratio as per explanations below.	<ul style="list-style-type: none"> <li>- Reasoned assessment for each involved entity of the projected quarterly cash needs for the period up to December 2021, starting with the current quarter (mix of actual and projection), taking into account at least cash flows from operations, cash outflows from planned investments and cash outflows from maturing debt, and</li> <li>- Cash balance available at the end of the previous quarter and the date at which the information is requested, and</li> <li>- Copy of the profit and loss accounts, cash flow statements (if available) and balance sheet for the last two years for which accounts have been closed from each concerned involved entity, or, failing that,</li> <li>- Appropriate statements from banks. The most recent year must have been closed within the last 18 months, or</li> <li>- Any other document allowing to calculate the ratio below.</li> </ul>	YES/NO	
T1	The tenderer must have implemented, within the company, Good manufacturing practice (hereafter, GMP) or GMP equivalent standards in its production processes.	<ul style="list-style-type: none"> <li>- Copy of a valid EU GMP certificate issued by a competent authority; or failing that,</li> <li>- Confirmation by an authorised body of the country where production takes place that it conforms to GMP standards equivalent to those in the EU.</li> </ul>	YES/NO	
T2	The tenderer must have implemented, within the company, a Quality Management System, based on ISO 9001 or equivalent, in respect of the activities subject of this call for tender.	<ul style="list-style-type: none"> <li>- Copy of valid ISO 9001 certificate or equivalent; or, failing that,</li> <li>- Document demonstrating that the tenderer has implemented a Quality Management System for the services within its company based on ISO 9001 or equivalent.</li> </ul>	YES/NO	

No	Criterion	Documents to be submitted regarding criterion	Methodology of scoring points	Maximum points
	<b>PRICE</b>			<b>Σ 100</b>
	Cost of development and production of one dose of vaccine		<ul style="list-style-type: none"> <li>- <b>40 points</b> will be score if Pr is between 20 EUR and 30 EUR</li> <li>- <b>60 points</b> will be scored if Pr is between 12 EUR and 20 EUR</li> <li>- <b>80 points</b> will be score if Pr is between 8 EUR and 12 EUR</li> <li>- <b>100 points</b> will be score if Pr is below 8 EUR.</li> </ul>	<b>100</b>
	<b>QUALITY</b>			<b>Σ 100</b>
1.1	Roadmap towards starting clinical trials plans by in 2020	Technical offer demonstrating: <ul style="list-style-type: none"> <li>- Clinical trials plans.</li> <li>- If studies have started, the Clinical trial study descriptions.</li> </ul>	<ul style="list-style-type: none"> <li>- <b>10 points</b> will be scored to a tender that will demonstrate plans to enter clinical trials by end of October 2020</li> <li>- <b>5 points</b> will be scored to a tender that will demonstrate plans to enter clinical trials by end of December 2020</li> <li>- <b>0 points</b> will be scored to a tender that will demonstrate plans to enter clinical trials after end of December 2020</li> </ul>	10
1.2	Capacity for the development of a successful Covid-19 vaccine	Technical offer demonstrating a sound scientific approach and technology used, including drawing on any evidence related to quality, safety and efficacy already generated from the development phases, where available. (For example, a sound scientific approach would entail a detailed description of the approach to studies research in line with the applicable legislation, the WHO recommendation(s) and clinical studies in line with the guidance on the management of clinical trials during the COVID-19 (coronavirus) pandemic.)	<ul style="list-style-type: none"> <li>- <b>20 points</b> will be scored to a tender that will demonstrate very good capacity to develop a successful and safe vaccine</li> <li>- <b>10 points</b> will be scored to a tender that will demonstrate good capacity to develop a successful and safe vaccine</li> <li>- <b>0 points</b> will be scored to a tender that will demonstrate low capacity to develop a successful vaccine</li> </ul>	20

The price (P) will be evaluated using the following formula:

Cost of development and production of one dose of vaccine:  $\underline{Pr} = (UI + TPV) / QP$

where:

- **P** is the score for the price of the tender in question.
- **UI** is the total amount of the upfront payments (or investments) (step I).
- **TPV** is the total price of vaccines (step II).
- **QP** is the proposed number of doses

**UI =**

**TPV =**

(Cost of a dosis \* the proposed number of dos

**QP =**

**Pr =** #DIV/0!

$\Pi + TPV) / QP$

ts) (step I).

es)